Ovid Therapeutics Inc. (OVID) AI Stock Analysis

Ovid Therapeutics Inc., headquartered in New York, is a biopharmaceutical company established in 2014 that develops treatments for individuals and families affected by neurological disorders. Central to its pipeline is OV101, currently in Phase 2A clinical trials for fragile X syndrome. The company is also developing OV329, a GABA aminotransferase inhibitor targeting seizures associated with tuberous sclerosis complex and infantile spasms, and OV350, a small molecule therapy for epilepsies. Additional programs include OV882, a short hairpin RNA gene therapy for angelman syndrome, and OV815 for disorders linked to kinesin-family proteins. Ovid collaborates with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc.

Ovid has experienced significant revenue volatility across recent fiscal years. Revenue reached $208.4M in FY2021 with net income of $122.8M, but dropped to $1.5M in FY2022 with net income of -$51.4M. After generating $392,000 in FY2023 and $566,000 in FY2024, revenue grew 1181.3% to $7.3M in FY2025, alongside net income of -$17.4M and R&D expense of $25.6M. From FY2020 to FY2025, revenue decreased at a 5-year CAGR of -10.5%. Over the trailing twelve months ended June 30, 2026, revenue totaled $1.6M with an operating margin of -2100.7%, while quarterly revenue declined 88.3% year-over-year.

As of June 30, 2026, Ovid held $117.2M in cash and short-term investments alongside total debt of $12.7M, providing net cash of $104.5M. Total assets were $232.0M and shareholders' equity stood at $209.9M. The company shows a current ratio of 12.39 and a debt-to-equity ratio of 0.06. In FY2025, operating cash flow was -$38.3M and free cash flow was -$38.3M, while its share count expanded 8.2% over five years.

At its last close of $2.15 on October 16, 2026, Ovid had a market cap of $419.9M and an enterprise value of $399.2M. The stock trades at a price-to-sales multiple of 265.2x and an EV-to-revenue multiple of 252.2x, well above the median of its US-listed Healthcare peers at 4.1x price-to-sales. Its forward P/E ratio is 1.8x, compared to 17.3x for its peer group median. Over the past year, Ovid gained 36.9% compared to 16.8% for the S&P 500 (SPY), though its 5-year return of -40.3% lagged the index return of 83.0%.

Wall Street coverage consists of 12 Strong Buy ratings, with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $6.00, which is 179.1% above the last close of $2.15. For the fiscal year ending December 31, 2026, consensus estimates project EPS of -$0.36 on revenue of $791,620. For the next fiscal year, 9 analysts project EPS of -$0.37 on revenue of $325,620. Ovid has beaten EPS expectations in 2 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Ovid Therapeutics Inc. (OVID). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OVID income statement, OVID balance sheet, OVID key metrics, OVID analyst forecast, OVID chart. See the OVID stock overview for the latest quote and news.